NWPF

News ArchivesRead News

Michael J. Fox and Parkinson’s Disease

Thursday June 30, 2005

Exact causes still a mystery
Mary Kugler

About - Between one and one-and-a-half million Americans are affected by Parkinson’s disease, a disorder of the central nervous system. "Parkinson’s" is the overall term for at least six different categoriesof the disorder, which usually affects people age 50 or older.

About 10-20% of people with Parkinson’s are diagnosed before age 50; only half of these people are diagnosed before age 40. This is called juvenile Parkinson’s. Michael J. Fox, diagnosed at age 30 years old in 1991, is in this category.

Possible causes People with Parkinson’s disease have a shortage of a chemical that affects movement (called dopamine) in their brains.

Treatment of Parkinson’s disease has traditionally been with medication that can be made into dopamine in the brain (Sinemet), or by drugs that seem to affect the use of dopamine in the brain (Symmetrel, Eldepryl). Newer drugs, called dopamine agonists (Parlodel, Permax, Mirapex, Requip), activate dopamine-sensitive brain cells.

Surgical treatments One technique being investigated is high-frequency stimulation of a part of the brain called the subthalamic nucleus. This is known as deep brain stimulation. Brain tissue transplants using genetically-altered cells, fetal tissue, or pig tissue introduce cells to produce dopamine. New techniques for thalamotomy and pallidotomy, which destroy the "trouble-causing" cells in the brain using an electrode, are being developed.

Michael J. Fox has established The Michael J. Fox Foundation for Parkinson’s Research. He has spoken out in favor of stem cell research and has worked tirelessly to raise money for research. The Foundation Web site states, "Fox wholeheartedly believes that if there is a concentrated effort from the Parkinson’s community, elected representatives in Washington, DC, and (most importantly) the general public, researchers can pinpoint the cause of Parkinson’s and uncover a cure by 2010."

Recent News

Oct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show